Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Introducing SHOWW, the Only Telemedicine Company in the Industry Offering a FDA-Regulated 503B Pharmacy Compounded Semaglutide

SHOWW.com offers a simple solution for weight management. It uses compounded Semaglutide and Tirzepatide. Complete an online application. Then, get a personalized plan with fast delivery. You can track your progress with monthly check-ins. Low prices, expert doctor guidance, and obeying US regulations ensure a reliable service.

News provided by

SHOWW LLC

Jul 01, 2024, 10:45 ET

Share this article

Share toX

Share this article

Share toX

MIAMI, July 1, 2024 /PRNewswire/ -- Companies can tell their prospective customers anything, but a recently launched business prefers guaranteed results. SHOWW is a weight loss telemedicine brand offering compounded semaglutide, which is the active ingredient in medications like Wegovy® and Ozempic®. SHOWW sets itself apart from other similar companies in the industry with its ultra-high quality FDA-Regulated 503B Pharmacy Compounded Semaglutide.

Continue Reading
SHOWW your best self.
SHOWW your best self.

Semaglutide is an injectable medication initially prescribed as a diabetes treatment. The United States Food and Drug Administration approved it as a medical treatment for weight loss in 2021, and it has taken the world by storm since then. Recent research from the University of California, Los Angeles, shows semaglutide can be an effective way to help support weight loss by curbing appetite while reducing the risk of cancer, diabetes, and heart disease in overweight people.

Weight loss medications featuring semaglutide have been prominent in the medical community in recent years, but not all providers are the same. Many brand-name semaglutide products can cost over $1,200 monthly. At SHOWW, customers enjoy the same level of quality and safety for a quarter of the price. The company uses clear pricing and transparent processes, with no hidden fees or manipulative tactics.

Standing Out in the Crowd

Telemedicine is an emerging industry, and many people may not know how simple it can be to speak with a doctor, get a prescription, and order recurring medication delivery from the comfort of home. At SHOWW, there are no appointments or wait times, and clients can receive their semaglutide in as little as four days.

SHOWW is the only semaglutide provider that employs a team of licensed doctors specializing in weight loss exclusively to prescribe medication and monitor patients' progress. These physicians do not offer any other services outside personalized weight loss solutions. The in-house team ensures clients aren't forced to endure long wait times to receive a prescription and treatment while preventing crossed wires or communication delays.

Safe and Reliable Solutions

As the usage of semaglutide grows, it becomes increasingly important for consumers to ensure they receive safe, accurate prescription medications. With SHOWW, clients experience premium telemedicine solutions and a reliable, personalized approach to their healthcare.

SHOWW's products are manufactured in a $250 million 503B compounding pharmacy. Unlike 503A facilities, every process at SHOWW must be validated. All medications are submitted for testing prior to being released for sale, ensuring every prescription leaving the facility is of consistent quality and meets all regulatory guidelines. This testing allows 503B compounding pharmacies to guarantee they produce the highest-quality products fit for use in doctor's offices, clinics, and hospitals.

The popularity of semaglutide as a weight loss medication has been so widespread that many areas have experienced shortages. SHOWW's 503B compounding pharmacy manufactures its products independently, so its productivity isn't dependent on external supply chains, and customers will not experience shortages.

Delivering Guaranteed Results

The internet is rife with scam companies out to take a customer's money without making a timely delivery of the product as described. SHOWW works to offer clients as much transparency, security, and convenience as possible while reliably delivering high-quality medication.

Clients enjoy fast, free shipping at SHOWW. All orders ship within 24 hours through FedEx or a two-day UPS courier, which means customers receive their medication less than four days after ordering it. Unlike many online providers, SHOWW always has semaglutide in stock, and customers never have to worry about inconvenient delays or issues refilling their medication.

According to a litany of customer complaints filed with the Better Business Bureau, many telemedicine providers rely on automated customer support. By contrast, SHOWW offers its clients 24/7 assistance via phone, email, SMS, or live chat. The customer's experience and satisfaction are a priority for SHOWW, and it works to ensure clients can always find answers to their questions. The team is entirely based in the United States, and live representatives are available from 9 a.m. to 6 p.m. EDT daily. All inquiries are answered within 24 hours.

Medicine-Assisted Weight Management in Four Steps

Getting started with SHOWW is a simple process. Start by completing an online application. In five minutes, clients learn whether SHOWW can help support their weight loss goals. If they are a good match, a licensed doctor will review their information and decide whether semaglutide is an appropriate treatment.

"Online consultations at SHOWW are typically free," representatives said. "You'll only pay for the prescription if you qualify after your medical consultation."

Once a doctor prescribes the medication, the order is passed on to SHOWW's 503B compounding pharmacy partner and delivered in under four days. As treatments continue, patients monitor their progress and measure it against their goals during monthly doctor check-ins.

"We aim to ensure every patient understands their treatment and achieves the best results," SHOWW founders said. "Our support team and physicians are available for free, unlimited follow-ups."

In addition to semaglutide, SHOWW offers GLP-1 medications like tirzepatide, which is the active ingredient in similar products like Zepbound™ and Mounjaro®. The company's team of qualified weight loss specialists will determine the most appropriate medications for an individual client's treatment goals, which may include additional drugs like metformin. Semaglutide prescription is not guaranteed for every client and is dependent upon physician approval. Semaglutide treatment is generally not recommended for individuals with a history of medullary thyroid cancer, gallbladder disease, pancreatitis, or multiple endocrine neoplasia syndrome type 2.

"Your health journey is unique, and so is our approach to your care," SHOWW founders said. "Rest assured, your treatment plan will be as unique as you are."

Affordable and Accessible

While SHOWW does not currently accept insurance coverage for its services, the products it provides can often be less expensive than many co-payments. Offering free virtual consultations further reduces the costs and makes medication-assisted weight loss affordable and accessible to ideal candidates.

With SHOWW, affordable telemedicine weight loss solutions are available to all qualified patients in the United States. Not only do customers reliably receive their semaglutide medication on time, but they can rest assured that refill prescriptions will also arrive on time and they'll never be left in dark due to shortages or backlogs.

Welcome to the SHOWW

When it comes to online solutions for weight loss, one telemedicine brand prefers to SHOWW rather than tell. Visit the SHOWW website to learn more about the telemedicine brand or to schedule a free weight loss consultation. It takes less than five minutes to complete the initial online application and discover whether semaglutide might be an appropriate treatment option.

Current and prospective customers may also contact SHOWW at (888) 413-7469 or email [email protected]. The brand maintains an online presence on Facebook and Instagram for those who wish to contact SHOWW for social media purposes.

SOURCE SHOWW LLC

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.